Aktuelle News
News Funktionen
Weitere Funktionen
4 April 2024
Immunic AG
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
20 März 2024
Immunic AG
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
7 März 2024
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in March
29 Februar 2024
Immunic AG
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
22 Februar 2024
Immunic AG
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
15 Februar 2024
Immunic AG
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
1 Februar 2024
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in February
5 Januar 2024
Immunic AG
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Immunic AG
Immunic, Inc. Announces Private Placement of up to $240 Million
21 November 2023
Immunic AG
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis
2 November 2023
Immunic AG
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
26 Oktober 2023
Immunic AG
Immunic to Participate in Scientific and Industry Conferences in November
16 Oktober 2023
Immunic AG
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
15 Oktober 2023
Immunic AG
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
11 Oktober 2023
Immunic AG
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
9 Oktober 2023
Immunic AG
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
4 Oktober 2023
Immunic AG
Immunic to Participate in Scientific Conferences in October
6 September 2023
Immunic AG
Immunic to Participate in Industry and Investor Conferences in September
17 August 2023
Immunic AG
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
1 August 2023
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in August
29 Juni 2023
Immunic AG
Immunic to Participate in Scientific and Investor Conferences in July
30 Mai 2023
Immunic AG
Immunic to Participate in Scientific and Investor Conferences in June
17 Mai 2023
Immunic AG
Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
6 Mai 2023
Immunic AG
Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
4 Mai 2023
Immunic AG
Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
27 April 2023
Immunic AG
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
26 April 2023
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in May
5 April 2023
Immunic AG
Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
2 März 2023
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in March
22 Februar 2023
Immunic AG
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023